SynthesisCritical reviews in oncology/hematology2017

Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Garrett K Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.